<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Chem Biol</journal-id><journal-id journal-id-type="iso-abbrev">ACS Chem Biol</journal-id><journal-id journal-id-type="publisher-id">cb</journal-id><journal-id journal-id-type="coden">acbcct</journal-id><journal-title-group><journal-title>ACS Chemical Biology</journal-title></journal-title-group><issn pub-type="ppub">1554-8929</issn><issn pub-type="epub">1554-8937</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7684578</article-id><article-id pub-id-type="pmid">33054165</article-id><article-id pub-id-type="doi">10.1021/acschembio.0c00568</article-id><article-categories><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Isopedopeptins A&#x02013;H: Cationic Cyclic Lipodepsipeptides
from <italic>Pedobacter cryoconitis</italic> UP508 Targeting WHO Top-Priority
Carbapenem-Resistant Bacteria</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Nord</surname><given-names>Christina</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Bjerketorp</surname><given-names>Joakim</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Levenfors</surname><given-names>Jolanta J.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Cao</surname><given-names>Sha</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Str&#x000f6;mstedt</surname><given-names>Adam A.</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Guss</surname><given-names>Bengt</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Larsson</surname><given-names>Rolf</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Hughes</surname><given-names>Diarmaid</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>&#x000d6;berg</surname><given-names>Bo</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath10"><name><surname>Broberg</surname><given-names>Anders</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Molecular Sciences, Uppsala BioCentrum, <institution>Swedish University of Agricultural Sciences</institution>, P.O. Box 7015, SE-750 07 Uppsala, <country>Sweden</country></aff><aff id="aff2"><label>&#x02021;</label><institution>Ultupharma
AB</institution>, S&#x000f6;dra Rudbecksgatan
13, SE-752 36 Uppsala, <country>Sweden</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Medical Biochemistry and Microbiology, <institution>Uppsala University</institution>, P.O. Box 582, SE-751 23 Uppsala, <country>Sweden</country></aff><aff id="aff4"><label>&#x02225;</label>Department
of Medicinal Chemistry, <institution>Uppsala University</institution>, P.O. Box 574, SE-751 23 Uppsala, <country>Sweden</country></aff><aff id="aff5"><label>&#x022a5;</label>Department
of Biomedical Sciences and Veterinary Public Health, <institution>Swedish University of Agricultural Sciences</institution>, P.O. Box 7036, SE-750
07 Uppsala, <country>Sweden</country></aff><aff id="aff6"><label>#</label>Department
of Medical Sciences, <institution>Uppsala University</institution>, SE-751 85 Uppsala, <country>Sweden</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>Anders.Broberg@slu.se</email>. Tel.: <phone>+46-18-672217</phone>.</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="ppub"><day>20</day><month>11</month><year>2020</year></pub-date><volume>15</volume><issue>11</issue><fpage>2937</fpage><lpage>2944</lpage><history><date date-type="received"><day>11</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>07</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 American Chemical Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical
Society</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Attribution (CC-BY) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html">License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb0c00568_0005" id="ab-tgr1"/></p><p><italic>Pedobacter cryoconitis</italic> strain UP508 was isolated
from a soil sample using a mixture of ampicillin, kanamycin, and nalidixic
acid for selection. UP508 was found to produce &#x0003e;30 unknown antibacterial
peptides, of which eight, isopedopeptins A&#x02013;H (<bold>1</bold>&#x02013;<bold>8</bold>), were isolated by bioassay-guided fractionation
and characterized with respect to structures and biological properties.
Compounds <bold>1</bold>&#x02013;<bold>8</bold> were all composed of
nine amino acid residues and one 3-hydroxy fatty acid residue, and
the structures were ring-closed via an ester bond from the C-terminal
aspartic acid to the 3-hydroxy fatty acid. The differences between
the peptides were the size and branching of the 3-hydroxy fatty acid
and the presence of a valine or a 3-hydroxyvaline residue. The isopedopeptins
mainly had activity against Gram-negative bacteria, and isopedopeptin
B (<bold>2</bold>), which had the best combination of antibacterial
activity, <italic>in vitro</italic> cytotoxicity, and hemolytic properties,
was selected for further studies against a larger panel of Gram-negative
bacteria. Isopedopeptin B was found to have good activity against
strains of WHO top-priority Gram-negative bacteria, i.e., carbapenem-resistant <italic>Acinetobacter baumannii</italic>, <italic>Escherichia coli</italic>, and <italic>Pseudomonas aeruginosa</italic>, with minimal inhibitory
concentrations (MIC) down to 1, 2, and 4 &#x003bc;g/mL, respectively.
Furthermore, compound <bold>2</bold> had activity against colistin-resistant
strains of <italic>A. baumannii</italic>, <italic>E. coli</italic>, and <italic>Klebsiella pneumoniae</italic>, with a MIC down to
8, 2, and 4 &#x003bc;g/mL, respectively. Compound <bold>6</bold> was
tested in an <italic>E. coli</italic> liposome system where it induced
significant leakage, indicating membrane disruption as one mechanism
involved in isopedopeptin antibacterial activity. Isopedopeptin B
stands out as a promising candidate for further studies with the goal
to develop a new antibiotic drug.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>cb0c00568</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>cb0c00568</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">The global
spread of antibiotic
resistance threatens many aspects of modern healthcare, and in the
future even the simplest infection or any routine surgery may be dangerous
without access to efficient and safe antibiotics. In Europe, infections
caused by antibiotic-resistant bacteria are responsible for the deaths
of more than 30&#x0202f;000 individuals per year,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> and estimations in the U.S. show similar figures.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> The situation is expected to escalate in the
years to come. To manage this serious problem, humanity needs access
to new antibiotic drugs but also regulations to limit the spread of
resistance against present and future antibiotic drugs.</p><p>A large
proportion of the antibacterial drugs used today, and in
the past, originate from nature&#x02014;either as molecules isolated
from microorganisms or developed from such molecules. Fungi and bacteria
produce compounds with antimicrobial properties, with the assumed
function to mediate interactions with competing microorganisms, to
bring benefits to the producers. One important group of natural compounds
used as antibiotic drugs are peptides produced by fungi or bacteria,
and vancomycin, penicillins, and cephalosporins are all classical
examples of such peptides which influence cell-wall synthesis in the
target bacteria. Over the years, these peptides have served as models
for the development of related improved antibiotic drugs, such as
extended-spectrum penicillins, fourth-generation cephalosporins, and
the recent semisynthetic vancomycin derivative telavancin. Another
important group of peptide antibiotics are the cyclic lipopeptides,
which have a cyclic peptide core carrying a fatty acid tail, exemplified
by the cationic peptide colistin and the anionic peptide daptomycin.
Colistin was introduced more than 60 years ago for the treatment of
Gram-negative infections, but due to toxicity issues, its use decreased
in the 1980s, and now it is used mainly as a last-resort antibiotic
against multidrug-resistant infections. Daptomycin was approved by
the FDA in 2003, for treatment of, e.g., complicated skin and skin
structure infections caused by Gram-positive bacteria. Cationic peptides
typically exert their antibacterial activity by interaction with negatively
charged components of the bacterial membrane and disrupting its cohesion,
and in the case of colistin, this includes specific interaction with
bacterial lipopolysaccharides (LPS).<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> The mechanism
of action of the anionic daptomycin involves calcium dependent oligomerization
and membrane insertion, causing membrane leakage.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Antibacterial peptides, produced by microorganisms, are
commonly produced by nonribosomal peptide synthases (NRPS). Nonribosomal
peptides often contain nonproteinogenic amino acid residues, such
as <sc>d</sc>-amino acids and a great variety of modified amino acid
residues. Examples of such modified residues are the oxidized and
chlorinated tyrosine residues and cross-linked phenylglycin residues
in vancomycin and the &#x003b2;-lactam-thiazolidine structure of penicillins,
that is formed by modification of an NRPS produced tripeptide precursor.</p><p>Despite the impressive track record of antibiotics discovery in
nature, it was out of fashion for a couple of decades to screen microorganisms
for the production of new antibiotics candidates, but in recent years,
fungi and bacteria are again considered as promising sources for new
chemical entities for development into antibiotic drugs.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref7">7</xref></sup> One major challenge when searching for new antibiotic compounds
in microorganisms is to find novel drug-producing microbial strains
to investigate. The recently described drug candidate teixobactin<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> was discovered in a bacterial strain isolated
using methods targeting previously uncultured bacteria,<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> which are estimated to be well over 90% of all
bacterial species in environmental samples. This methodology is expected
to open up an exciting untapped source of bacterial strains for the
production of novel and interesting bacterial compounds. Another recent
approach to obtain previously unexploited drug-producing microbial
strains is to use antibiotic resistance-based isolation of microorganisms.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> This technique is based on the inherent need
for antibiotic producing microorganisms to carry genes for &#x0201c;self-resistance,&#x0201d;
which makes resistant microorganisms likely candidates to produce
antibiotic compounds.</p><p>The present paper describes the isolation
and characterization
of a family of antibacterial cyclic lipodepsipeptides, isopedopeptin
A&#x02013;H (<bold>1</bold>&#x02013;<bold>8</bold>) from the bacterium <italic>Pedobacter cryoconitis</italic> strain UP508, which was isolated
from a soil sample using a resistance-based approach. Several of these
peptides display activity against many important clinical strains
of Gram-negative bacteria, including strains of all the WHO top-priority
human pathogens: carbapenem-resistant <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, and <italic>Enterobacteriaceae</italic>, as well as colistin-resistant strains of <italic>A. baumannii</italic>, <italic>Escherichia coli</italic>, and <italic>Klebsiella pneumoniae</italic>.</p><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Isolation of Compounds</title><p>Culture extracts
of <italic>P. cryoconitis</italic> UP508 were analyzed by UHPLC-MS,
followed
by database and literature comparison. The observation of the following
doubly charged ions ([M + 2H]<sup>2+</sup>), <italic>m</italic>/<italic>z</italic> 566.3251 (<bold>1</bold>), 559.3170 (<bold>2</bold>),
572.3243 (<bold>3</bold>), 551.3214 (<bold>4</bold>), 558.3278 (<bold>5</bold>), 580.3398 (<bold>6</bold>), 571.3356 (<bold>7</bold>),
and 571.3352 (<bold>8</bold>), suggested the presence of several unknown
compounds in the extracts. Most of the compounds also had [M + 3H]<sup>3+</sup> and [M + H]<sup>+</sup> ions, and the presence of several
different charge states suggested the compounds to be peptides. Subsequent
bioassay-guided fractionation of these <italic>P. cryoconitis</italic> UP508 culture extracts resulted in many fractions with activity
against both Gram-positive and Gram-negative bacteria, including the
bacterial pathogens <italic>E. coli</italic>, <italic>K. pneumoniae</italic>, <italic>Enterobacter cloacae</italic>, <italic>P. aeruginosa</italic>, and <italic>A. baumannii</italic>. Antibacterial fractions were
analyzed by UHPLC-MS, followed by database mining, which suggested
the presence of a large number (&#x0003e;30) of unknown antibacterial compounds
with molecular weights in the range 1100&#x02013;1160 Da, and all the
above suggested peptides (<bold>1</bold>&#x02013;<bold>8</bold>) were
present in antibacterial fractions. Subsequently, small amounts of
compounds <bold>1</bold> and <bold>2</bold>, along with several of
the other compounds above, were obtained in semipure form after another
round of preparative HPLC. MIC determination gave preliminary values
&#x0003c;10 &#x003bc;g/mL against strains of <italic>E. coli</italic>, <italic>A. baumannii</italic>, <italic>E. cloacae</italic>, and <italic>K.
pneumoniae</italic> for several of the compounds, indicating them
to be interesting for further studies. Subsequently, the cultivation
of the UP508 isolate was optimized along with the method for isolation
of the compounds, which allowed the isolation of compounds <bold>1</bold>&#x02013;<bold>8</bold> (between 0.66 mg and 7.95 mg each), for further
characterization with respect to structure and biological properties.</p></sec><sec id="sec2.2"><title>Structure Determination</title><p>Compound <bold>1</bold> was
found to have an [M + 2H]<sup>2+</sup> ion of <italic>m</italic>/<italic>z</italic> 566.3243, corresponding to <italic>m</italic>/<italic>z</italic> 1131.6413 for the [M + H]<sup>+</sup> ion. NMR in DMSO-<italic>d</italic><sub>6</sub> (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>) gave spin-systems in accord with the presence of the standard
amino acid residues Phe, Thr, Leu, and Asp. In addition, several spin-systems
suggested several nonproteinogenic amino acids to be present in <bold>1</bold>, along with a 3-hydroxy fatty acid residue (3OHFA), as outlined
below. Compound <bold>1</bold> was thus concluded to be a peptide.
MSMS on compound <bold>1</bold> gave poor yields of fragment ions,
which indicated a cyclic structure for <bold>1</bold>.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title><sup>1</sup>H and <sup>13</sup>C NMR
Data (600 and 150 MHz, resp) for Compound <bold>1</bold> (DMSO-<italic>d</italic><sub>6</sub>, 30&#x000b0;C)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">pos.</th><th style="border:none;" align="center" char="."><sup>13</sup>C</th><th style="border:none;" align="center" char="."><sup>1</sup>H</th><th style="border:none;" align="center">mult (<italic>J</italic>, Hz)</th><th style="border:none;" align="center">pos.</th><th style="border:none;" align="center" char="."><sup>13</sup>C</th><th style="border:none;" align="center" char="."><sup>1</sup>H</th><th style="border:none;" align="center">mult (<italic>J</italic>, Hz)</th></tr></thead><tbody><tr><td style="border:none;" align="left">3OHFA</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">Thr</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">167.6</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.42</td><td style="border:none;" align="left">d (7.6)</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">39.4</td><td style="border:none;" align="char" char=".">2.69</td><td style="border:none;" align="left">dd (13.8, 3.5)</td><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">169.4</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">2.17</td><td style="border:none;" align="left">dd (13.8, 4.1)</td><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">59.5</td><td style="border:none;" align="char" char=".">4.20</td><td style="border:none;" align="left">dd (7.8, 2.3)</td></tr><tr><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">70.7</td><td style="border:none;" align="char" char=".">4.97</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">65.0</td><td style="border:none;" align="char" char=".">4.35</td><td style="border:none;" align="left">dq (2.5, 6.5)</td></tr><tr><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">31.2</td><td style="border:none;" align="char" char=".">1.49</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">20.4</td><td style="border:none;" align="char" char=".">1.22</td><td style="border:none;" align="left">d (6.5)</td></tr><tr><td style="border:none;" align="left"><bold>5</bold></td><td style="border:none;" align="char" char=".">26.1</td><td style="border:none;" align="char" char=".">1.20</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left">DAPA2</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>6</bold></td><td style="border:none;" align="char" char=".">28.6</td><td style="border:none;" align="char" char=".">1.21</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.18</td><td style="border:none;" align="left">d (8.7)</td></tr><tr><td style="border:none;" align="left"><bold>7</bold></td><td style="border:none;" align="char" char=".">25.0</td><td style="border:none;" align="char" char=".">1.20</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">169.1</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>8</bold></td><td style="border:none;" align="char" char=".">38.0</td><td style="border:none;" align="char" char=".">1.12</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">53.2</td><td style="border:none;" align="char" char=".">4.22</td><td style="border:none;" align="left">ddd
(8.7, 8.7, 5.7)</td></tr><tr><td style="border:none;" align="left"><bold>9</bold></td><td style="border:none;" align="char" char=".">27.0</td><td style="border:none;" align="char" char=".">1.49</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">40.6</td><td style="border:none;" align="char" char=".">3.04</td><td style="border:none;" align="left">dd (13.1, 5.7)</td></tr><tr><td style="border:none;" align="left"><bold>10</bold></td><td style="border:none;" align="char" char=".">22.1</td><td style="border:none;" align="char" char=".">0.84</td><td style="border:none;" align="left">d (6.6)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">2.87</td><td style="border:none;" align="left">obsc</td></tr><tr><td style="border:none;" align="left"><bold>11</bold></td><td style="border:none;" align="char" char=".">22.1</td><td style="border:none;" align="char" char=".">0.84</td><td style="border:none;" align="left">d (6.6)</td><td style="border:none;" align="left">Phe</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">DAPA1</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">7.26</td><td style="border:none;" align="left">d (9.0)</td></tr><tr><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.57</td><td style="border:none;" align="left">d (9.1)</td><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">171.5</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">170.8</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">53.5</td><td style="border:none;" align="char" char=".">4.76</td><td style="border:none;" align="left">obsc</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">50.6</td><td style="border:none;" align="char" char=".">4.73</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">37.6</td><td style="border:none;" align="char" char=".">2.89</td><td style="border:none;" align="left">obsc</td></tr><tr><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">43.9</td><td style="border:none;" align="char" char=".">3.12</td><td style="border:none;" align="left">dd (13.1, 5.4)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">2.72</td><td style="border:none;" align="left">obsc</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">2.97</td><td style="border:none;" align="left">dd (13.1, 4.1)</td><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">137.2</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">Leu</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left"><bold>5</bold>/<bold>9</bold></td><td style="border:none;" align="char" char=".">129.2</td><td style="border:none;" align="char" char=".">7.34</td><td style="border:none;" align="left">m</td></tr><tr><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.89</td><td style="border:none;" align="left">br s</td><td style="border:none;" align="left"><bold>6</bold>/<bold>8</bold></td><td style="border:none;" align="char" char=".">127.6</td><td style="border:none;" align="char" char=".">7.21</td><td style="border:none;" align="left">m</td></tr><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">173.1</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left"><bold>7</bold></td><td style="border:none;" align="char" char=".">125.8</td><td style="border:none;" align="char" char=".">7.15</td><td style="border:none;" align="left">m</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">52.8</td><td style="border:none;" align="char" char=".">4.33</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left">3OHVal</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">39.1</td><td style="border:none;" align="char" char=".">1.65</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.59</td><td style="border:none;" align="left">d (9.6)</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">1.46</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">169.4</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">24.0</td><td style="border:none;" align="char" char=".">1.65</td><td style="border:none;" align="left">obsc</td><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">58.0</td><td style="border:none;" align="char" char=".">4.72</td><td style="border:none;" align="left">obsc</td></tr><tr><td style="border:none;" align="left"><bold>5</bold></td><td style="border:none;" align="char" char=".">22.2</td><td style="border:none;" align="char" char=".">0.88</td><td style="border:none;" align="left">d (6.2)</td><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">70.6</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>6</bold></td><td style="border:none;" align="char" char=".">22.2</td><td style="border:none;" align="char" char=".">0.84</td><td style="border:none;" align="left">d (6.1)</td><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">26.4</td><td style="border:none;" align="char" char=".">1.05</td><td style="border:none;" align="left">s</td></tr><tr><td style="border:none;" align="left">DABA</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left"><bold>5</bold></td><td style="border:none;" align="char" char=".">26.5</td><td style="border:none;" align="char" char=".">0.92</td><td style="border:none;" align="left">s</td></tr><tr><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.65</td><td style="border:none;" align="left">d (9.3)</td><td style="border:none;" align="left">Asp</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">168.0</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">8.52</td><td style="border:none;" align="left">d (9.6)</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">49.5</td><td style="border:none;" align="char" char=".">4.64</td><td style="border:none;" align="left">ddd (9.3, 7.0, 7.0)</td><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">173.9</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">29.2</td><td style="border:none;" align="char" char=".">1.82</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">48.4</td><td style="border:none;" align="char" char=".">4.74</td><td style="border:none;" align="left">obsc</td></tr><tr><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">35.4</td><td style="border:none;" align="char" char=".">2.75</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">40.5</td><td style="border:none;" align="char" char=".">2.84</td><td style="border:none;" align="left">dd (16.1,
4.5)</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">2.61</td><td style="border:none;" align="left">m</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">2.23</td><td style="border:none;" align="left">d (16.1, 3.8)</td></tr><tr><td style="border:none;" align="left">ABA</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">174.4</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">NH</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">10.22</td><td style="border:none;" align="left">br s</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">165.4</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>2</bold></td><td style="border:none;" align="char" char=".">132.6</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>3</bold></td><td style="border:none;" align="char" char=".">114.1</td><td style="border:none;" align="char" char=".">5.57</td><td style="border:none;" align="left">q (7.3)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left"><bold>4</bold></td><td style="border:none;" align="char" char=".">12.5</td><td style="border:none;" align="char" char=".">1.77</td><td style="border:none;" align="left">d (7.3)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="char" char=".">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr></tbody></table></table-wrap><p>Two spin systems, NH&#x02013;CH&#x02013;CH<sub>2</sub>, with chemical
shifts for the CH<sub>2</sub> groups in agreement with linkages to
amino groups (&#x003b4;<sub>H</sub> 3.12/2.91, &#x003b4;<sub>C</sub> 43.9,
and &#x003b4;<sub>H</sub> 3.04/2.87, &#x003b4;<sub>H</sub> 40.6, respectively),
suggested the presence of two 2,3-diaminopropanoic acid residues (DAPA)
in compound <bold>1</bold>. A similar spin-system, but extended by
a CH<sub>2</sub> group, i.e., NH&#x02013;CH&#x02013;CH<sub>2</sub>&#x02013;CH<sub>2</sub>, suggested a 2,4-diaminobutanoic acid residue (DABA) to be
present in <bold>1</bold>. Three basic amino acids in <bold>1</bold>, i.e., two DAPA residues and one DABA residue, were in agreement
with the presence of an intense [M + 3H]<sup>3+</sup> ion for the
peptide in MS analysis. One further spin system was NH&#x02013;CH,
and by HMBC correlations (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A) the methine group was determined to be linked to
a quarternary carbon (&#x003b4;<sub>C</sub> 70.6) which was linked to
two methyl groups and, as judged by the chemical shift, to a hydroxy
group. This suggested the presence of a 3-hydroxyvaline residue (3OHVal)
in compound <bold>1</bold>. The final proposed nonproteinogenic amino
acid residue in <bold>1</bold> had a methyl group (&#x003b4;<sub>H</sub> 1.77, &#x003b4;<sub>C</sub> 12.5) which was linked to an sp<sup>2</sup> CH (&#x003b4;<sub>H</sub> 5.57, &#x003b4;<sub>C</sub> 114.1). By HMBC
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A), this sp<sup>2</sup> carbon was determined to be linked to another sp<sup>2</sup> carbon (&#x003b4;<sub>C</sub> 132.6) and subsequently to a carbonyl
(&#x003b4;<sub>C</sub> 165.4). If the carbon at &#x003b4;<sub>C</sub> 132.6
was linked to an amino function, this would make up a 2-amino-2-butenoic
acid residue (ABA), described to be present in many microbial nonribosomal
peptides, with <italic>Z</italic>-geometry<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> or with <italic>E</italic>-geometry.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> In the 1D <sup>1</sup>H NMR spectrum of <bold>1</bold>, there were
nine signals from putative amide protons, and eight of these signals
were already assigned to the amino acid residues Phe, Thr, Leu, Asp,
2 &#x000d7; DAPA, DABA, and OHVal, using data from COSY, TOCSY, and HSQC-TOCSY.
The remaining putative amide signal (broad signal at &#x003b4;<sub>H</sub> 10.22) was thus assigned as the tentative ABA amide proton. Subsequently,
ROESY experiments gave a cross-peak between this signal and the ABA
olefinic signal (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A), which supported the assignment of the signal at &#x003b4;<sub>H</sub> 10.22 as the ABA amide proton, but also suggested the ABA residue
to be in the <italic>E</italic>-configuration in <bold>1</bold>. The
proposed 3OHFA, with the spin-system CH<sub>2</sub>&#x02013;CH&#x02013;CH<sub>2</sub>&#x02013;CH<sub>2</sub>&#x02013;(CH<sub>2</sub>)<italic><sub>n</sub></italic>&#x02013;CH<sub>2</sub>&#x02013;CH(CH<sub>3</sub>)&#x02013;CH<sub>3</sub>, was identified by combination of COSY, TOCSY, HSQC, and
HMBC NMR data. The terminal CH<sub>2</sub> had chemical shifts and
a coupling pattern in agreement with the linkage to a carbonyl (&#x003b4;<sub>H</sub> 2.69/2.17, <sup>2</sup><italic>J</italic> 13.8 Hz, &#x003b4;<sub>C</sub> 39.4) and chemical shifts for the adjacent CH in accord with
linkage to an esterified hydroxy function (&#x003b4;<sub>H</sub> 4.97,
&#x003b4;<sub>C</sub> 70.7). HMBC data verified the linkage of the terminal
CH<sub>2</sub> to a carbonyl group (&#x003b4;<sub>C</sub> 167.6).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(A) Key HMBC
(solid single-headed arrows) and ROESY (dashed double-headed
arrows) correlations for structure determination of compound <bold>1</bold>. (B) Determination of absolute configuration of the 3-hydroxydecanoic
acid originating from compound <bold>1</bold>, by NMR analysis of
Mosher esters.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Selected <sup>1</sup>H
NMR chemical shifts obtained in CHCl<sub>3</sub>-<italic>d</italic> are displayed on top, and the calculated chemical shifts differences
(R-S) below, along with the indicated absolute configuration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb0c00568_0001" id="gr1" position="float"/></fig><p>By comparison of the <italic>m</italic>/<italic>z</italic> for
the [M + H]<sup>+</sup> ion of <bold>1</bold> (1131.6413), with the
sum of the individual masses of the different amino acid residues
(Phe, Thr, Leu, Asp, 2 &#x000d7; DAPA, DABA, 3OHVal and ABA), a nice
fit was obtained when adding the mass for a 3-hydroxy-9-methylhydroxydecanoic
acid residue (theoretical <italic>m</italic>/<italic>z</italic> 1131.6408
for the [M + H]<sup>+</sup> ion, difference 0.4 ppm). Thus, compound <bold>1</bold> was suggested to be a cyclic lipodepsipeptide containing
a 3-hydroxy-9-methyldecanoic acid together with nine amino acid residues.</p><p>As mentioned above, MSMS on the native peptide gave poor yields
of sequence fragment ions, in accord with <bold>1</bold> being a cyclic
lipodepsipeptide. Thus, the peptide was treated with dilute NaOMe
in MeOH to open the presumed lactone. Analysis by MS showed that MeOH
indeed had been added to the structure ([M + 2H]<sup>2+</sup><italic>m</italic>/<italic>z</italic> 582.334), and subsequent MSMS analysis
gave informative fragment ions which were used for the determination
of the amino acid sequence of <bold>1</bold> (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The B-fragment ion series B<sub>1</sub>&#x02013;B<sub>8</sub> was in good agreement with the sequence (3-hydroxy-9-methyldecanoyl-DAPA)-Leu-DABA-ABA-Thr-DAPA-Phe-3OHVal-Asp-OMe,
and this sequence was corroborated by the Y-fragment ion series Y<sub>2</sub>&#x02013;Y<sub>8</sub>. The 3-hydroxy-9-methyldecanoyl CH group
had chemical shifts (&#x003b4;<sub>H</sub> 4.97, &#x003b4;<sub>C</sub> 70.7) in accord with linkage to an esterified hydroxy function,
and furthermore, if the lactone would have been closed to the hydroxy
function of either the Thr or 3OHVal residue, informative N-terminal
sequence fragment ions would have been expected in MSMS analysis of
the native peptide. Thus, compound <bold>1</bold> was proposed to
have the structure <italic>cyclo</italic>(3-hydroxy-9-methyldecanoyl-DAPA1-Leu-DABA-ABA-Thr-DAPA2-Phe-OHVal-Asp)
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>MSMS spectrum
of compound <bold>1</bold> after ring-opening with
NaOMe in MeOH. The <italic>m</italic>/<italic>z</italic> for sequence
ions B<sub>1</sub>&#x02013;B<sub>8</sub> and Y<sub>2</sub>&#x02013;Y<sub>8</sub> are shown in the spectrum, along with the corresponding amino
acid sequences. Theoretical <italic>m</italic>/<italic>z</italic> values
for the observed B- and Y-series ions are shown in the structure on
top.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb0c00568_0002" id="gr2" position="float"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Structures of isopedopeptins A&#x02013;H (<bold>1</bold>&#x02013;<bold>8</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb0c00568_0003" id="gr3" position="float"/></fig><p>The MS&#x02013;MS based amino acid sequence was verified by ROESY
and HMBC experiments (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A). The following ROESY cross-peaks were observed: 3OHFA H-2/DAPA1
NH, DAPA1 H-2/Leu NH, Leu H-2/DABA NH, DABA H-2/ABA NH, ABA&#x02013;CH<sub>3</sub>/Thr NH, Thr NH/DAPA2 NH, DAPA2 NH/Phe NH, Phe H-2/3OHVal
NH, 3OHVal H-2/Asp NH (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>), along with the following HMBC cross-peaks: 3OHFA CO/DAPA1
NH, Leu CO/DABA NH, ABA CO/Thr NH, Thr CO/DAPA2 NH, DAPA2 CO/Phe NH,
Phe CO/3OHVal NH, and 3OHVal CO/Asp NH (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A).</p><p>The configuration of the amino
acids was determined using the advanced
Marfey&#x02019;s method,<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> by acidic hydrolysis
and derivatization with 1-fluoro-2,4-dinitrophenyl-5-<sc>l</sc>-leucinamide
(FDLA), followed by UHPLC-MS analysis. Comparison with commercial
reference amino acids enabled identification of the amino acids as
2 &#x000d7; L-DAPA, <sc>l</sc>-Leu, L-DABA, <sc>l</sc>-Thr, <sc>d</sc>-Phe, <sc>l</sc>-OHVal, and <sc>l</sc>-Asp. <sc>d</sc>-DAPA was also
detected in peptide hydrolysates, but hydrolysis of peptides in H<sub>2</sub>O/D<sub>2</sub>O mixtures demonstrated that D-DAPA was formed
by epimerization, as previously observed,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> and was thus not present in the peptide. Similarly, Phe was also
shown to epimerize during the acidic hydrolysis, but to a lesser extent
than DAPA.</p><p>The configuration of the 3-hydroxy-9-methyldecanoyl
residue in <bold>1</bold> was determined by Mosher&#x02019;s method.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> After release of the fatty acid by acidic hydrolysis
of
the peptide, the fatty acid was derivatized with (<italic>R</italic>)- and (<italic>S</italic>)-2-methoxy-2-trifluoromethyl-2-phenylacetyl
(MTPA) chloride. The crude products were analyzed by NMR in pyridine-<italic>d</italic><sub>5</sub> and chloroform-<italic>d</italic>. Comparison
of the proton chemical shifts of H-2, H-4, and H-5, between the products
obtained with <italic>R</italic>- and <italic>S</italic>-reagents
(i.e., (<italic>R</italic>)-MTPA&#x02013;Cl product &#x02013; (<italic>S</italic>)-MTPA&#x02013;Cl product) gave differences in line with
R-configuration of the 3-hydroxydecanoyl residue (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B). This was valid for both
NMR solvents. Thus, analysis by NMR and MS, along with chemical degradations
and derivatizations, resulted in the full structure of compound <bold>1</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>Compound <bold>2</bold> was found to have an [M + 2H]<sup>2+</sup> ion of <italic>m</italic>/<italic>z</italic> 559.3169, corresponding
to <italic>m</italic>/<italic>z</italic> 1117.6265 for the [M + H]<sup>+</sup> ion, which suggested a difference compared to <bold>1</bold> by a &#x02212;CH<sub>2</sub>&#x02013; group. NMR in DMSO-<italic>d</italic><sub>6</sub> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">Supplementary Table 2</ext-link>) indicated
the presence of the same amino acids as in <bold>1</bold>, along with
an unbranched 3-hydroxy fatty acid residue. By comparison of the <italic>m</italic>/<italic>z</italic> for the [M + H]<sup>+</sup> ion of <bold>2</bold> (1117.6265), with the added individual masses of the different
amino acid residues, a nice fit was obtained when adding the mass
for a 3-hydroxydecanoic acid residue (theoretical <italic>m</italic>/<italic>z</italic> 1117.6252 for the [M + H]<sup>+</sup> ion, difference
1.2 ppm). Thus, compound <bold>2</bold> was suggested to be a cyclic
lipodepsipeptide containing a 3-hydroxydecanoic acid together with
nine amino acid residues. Subsequent NaOMe/MeOH lactone opening and
MSMS analysis gave the sequence (3-hydroxydecanoyl-DAPA)-Leu-DABA-ABA-Thr-DAPA-Phe-OHVal-Asp-OMe,
and this sequence was corroborated by ROESY and HMBC correlations.
The configuration of the amino acids was determined by acidic hydrolysis
and derivatization with FDLA, followed by UHPLC-MS analysis, to be
the same as for <bold>1</bold>. Assuming the same configuration of
the 3-hydroxydecanoyl residue in <bold>2</bold> as for the (<italic>R</italic>)-3-hydroxy-9-methyldecanoyl residue of <bold>1</bold> resulted
in the full structure of <bold>2</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>Subsequently, compounds <bold>3</bold>&#x02013;<bold>8</bold> were
analyzed in analogy with compounds <bold>1</bold> and <bold>2</bold>, and their structures were found to be very similar to <bold>1</bold> and <bold>2</bold>, including the configuration of all amino acid
residues (<sc>d</sc>-Phe and <sc>l</sc>-configuration for all other
residues). The R-configuration of the 3OHFA residues was only determined
on <bold>1</bold> and was assumed to be the same on compounds <bold>2</bold>&#x02013;<bold>8</bold>. The main differences between compounds <bold>3</bold>&#x02013;<bold>8</bold> and compounds <bold>1</bold> and <bold>2</bold> are described below.</p><p>MS analysis of compound <bold>3</bold> resulted in <italic>m</italic>/<italic>z</italic> 572.3246
for the [M+2H]<sup>2+</sup> ion (<italic>m</italic>/<italic>z</italic> 1143.6419 for the [M + H]<sup>+</sup> ion). Compared to compounds <bold>1</bold> and <bold>2</bold>, MSMS
showed the structure difference to be in the 3OHFA part of the structure.
The 3OHFA of <bold>3</bold> was found to have 12 carbon atoms, and
additionally, one unsaturation or ring in the 3OHFA. NMR analysis
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">Supplementary Table 3</ext-link>) showed the 3OHFA
to be unbranched and to contain one double bond (two olefinic protons
at &#x003b4;<sub>H</sub> 5.27 and &#x003b4;<sub>H</sub> 5.40, respectively).
By COSY experiments, it was concluded that the double bond was located
at C-5/C-6 of the 3OHFA. The H-5/H-6 <sup>3</sup><italic>J</italic> was 11 Hz, which strongly suggested the 3OHFA in <bold>3</bold> to
be a <italic>cis</italic>-3-hydroxy-5-dodecenoyl residue (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>Compound <bold>4</bold> had a [M + 2H]<sup>2+</sup> ion at <italic>m</italic>/<italic>z</italic> 551.3194 and a [M + H]<sup>+</sup> ion
at <italic>m</italic>/<italic>z</italic> 1101.6315, suggesting a difference
corresponding to one oxygen atom compared to compound <bold>2</bold>. MSMS analysis showed the 3OHVal residue to be absent in <bold>4</bold>, and instead the data suggested a Val residue to be present. This
difference was later confirmed by NMR analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">Supplementary Table 4</ext-link>), which also showed the presence of
a 3-hydroxydecanoyl residue in <bold>4</bold>, just as in <bold>2</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>The [M + 2H]<sup>2+</sup> ion of compound <bold>5</bold> had <italic>m</italic>/<italic>z</italic> 558.3275, corresponding to <italic>m</italic>/<italic>z</italic> 1115.6477 for the [M + H]<sup>+</sup> ion. Just as for <bold>4</bold>, compound <bold>5</bold> was found
by MSMS to have a Val residue instead of a 3OHVal residue, and the
difference compared to <bold>4</bold> was located in the 3OHFA part
of the structure, which was found to have 11 carbon atoms. NMR analysis
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">Supplementary Table 5</ext-link>) subsequently showed
this 3OHFA was to be a 3-hydroxy-9-methyldecanoyl residue, just as
in <bold>1</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>Compound <bold>6</bold> was by MS ([M+2H]<sup>2+</sup><italic>m</italic>/<italic>z</italic> 580.3401, [M + H]<sup>+</sup><italic>m</italic>/<italic>z</italic> 1159.6729), MSMS, and NMR
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">Supplementary Table 6</ext-link>) found to be similar
to
compound <bold>1</bold>, the only difference being the number of carbons
in the 3OHFA. Compound <bold>6</bold> had a 3-hydroxy-11-methyldodecanoyl
residue compared to a 3-hydroxy-9-methyldecanoyl residue in <bold>1</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>Analysis by MS, MSMS, and NMR (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">Supplementary Tables 7 and 8</ext-link>) showed compounds <bold>7</bold> and <bold>8</bold> to be very similar to each other. They both contained Val instead
of 3OHVal residues, and they both contained <italic>cis</italic>-3-hydroxy-11-methyldodecenoyl
residues, but the location of the double bond was at C-7/C-8 in <bold>7</bold> and at C-5/C-6 in <bold>8</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p><p>Similar peptides, pedopeptin A&#x02013;C
and B12489A&#x02013;C, have
previously been isolated from <italic>Pedobacter</italic> sp. SANK
72003.<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup> These peptides are all cyclic lipodepsipeptides
based on one 3-hydroxy fatty acid residue and nine amino acid residues,
including one <italic>E</italic>-ABA residue. The main difference
between pedopeptin A&#x02013;C/B12489A&#x02013;C and compounds <bold>1</bold>&#x02013;<bold>8</bold> is that Leu and Phe have the opposite
positions in the pedopeptins/B12489A&#x02013;C compared to those in <bold>1</bold>&#x02013;<bold>8</bold>, and the Thr of <bold>1</bold>&#x02013;<bold>8</bold> is exchanged to Leu in pedopeptin A&#x02013;C/B12489A&#x02013;C.
Additionally, the structures of the 3-hydroxy fatty acid residues
are different in the pedopeptins/B12489A&#x02013;C compared to <bold>1</bold>&#x02013;<bold>8</bold>, with 3-hydroxyoctanoyl or 3-hydroxy-7-methyloctanoyl
residues in the pedopeptins/B12489A&#x02013;C compared to 3-hydroxydecanoyl
and larger residues in <bold>1</bold>&#x02013;<bold>8</bold>. On the
basis of the similarities and differences with the pedopeptins/B12489A&#x02013;C,
compounds <bold>1</bold>&#x02013;<bold>8</bold> were named isopedopeptin
A&#x02013;H.</p></sec><sec id="sec2.3"><title>Biological Properties</title><p>Compounds <bold>1</bold>&#x02013;<bold>8</bold> were tested against a panel of Gram-negative
and Gram-positive
bacteria, as well as against two fungi (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). In general, the activity against Gram-negative
bacteria was better than against Gram-positive bacteria, and the activity
against fungi was poor (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Compound <bold>1</bold> displayed the highest antibacterial
activities, with MIC values down to 4 &#x003bc;g/mL against the &#x003b2;-lactamase
producing <italic>E. coli</italic> LMG15862 and <italic>A. baumannii</italic> LMG1041<sup>T</sup>, whereas compounds <bold>2</bold> and <bold>7</bold> had the second-best antibacterial activities with MIC 8
&#x003bc;g/mL against these pathogens. Compounds <bold>1</bold>, <bold>2</bold>, and <bold>7</bold> also had promising MICs against <italic>P. aeruginosa</italic> LMG6395<sup>T</sup> and ESBL <italic>K. pneumoniae</italic> LMG20218, in the range 8&#x02013;16 &#x003bc;g/mL (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). The IC<sub>50</sub> values
against HepG2 cells varied substantially between the different compounds
(<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). Compound <bold>2</bold> had the highest IC<sub>50</sub> value (56 &#x003bc;g/mL) and <bold>2</bold> also had an acceptable hemolysis rate (&#x0003c;0.8%), whereas
compounds <bold>1</bold> and <bold>7</bold> had lower IC<sub>50</sub> values and substantially higher hemolysis rates (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>MIC Values
(&#x003bc;g/mL) for Compounds <bold>1</bold>&#x02013;<bold>8</bold> against
the Primary Panel of Bacteria
and Fungi, along with IC<sub>50</sub> Values (&#x003bc;g/mL) against
HepG2 Cells and Haemolysis Frequencies (ESBL, extended-spectrum &#x003b2;-lactamase;
MRSA, methicillin-resistant <italic>S. aureus</italic>)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">&#x000a0;</th><th colspan="8" align="center">compound<hr/></th></tr><tr><th style="border:none;" align="center">pathogen</th><th style="border:none;" align="center">strain</th><th style="border:none;" align="center">type</th><th style="border:none;" align="center"><bold>1</bold></th><th style="border:none;" align="center"><bold>2</bold></th><th style="border:none;" align="center"><bold>3</bold></th><th style="border:none;" align="center"><bold>4</bold></th><th style="border:none;" align="center"><bold>5</bold></th><th style="border:none;" align="center"><bold>6</bold></th><th style="border:none;" align="center"><bold>7</bold></th><th style="border:none;" align="center"><bold>8</bold></th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>E.
coli</italic></td><td style="border:none;" align="left">LMG15862</td><td style="border:none;" align="left">&#x003b2;-lactam.</td><td style="border:none;" align="center">4</td><td style="border:none;" align="center">8</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">8</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">LMG1041T</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">4</td><td style="border:none;" align="center">8</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">8</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>E. cloacae</italic></td><td style="border:none;" align="left">LMG2783T</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>K. pneumoniae</italic></td><td style="border:none;" align="left">LMG20218</td><td style="border:none;" align="left">ESBL</td><td style="border:none;" align="center">8</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic></td><td style="border:none;" align="left">LMG6395T</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">8</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>S. aureus</italic></td><td style="border:none;" align="left">LMG15975</td><td style="border:none;" align="left">MRSA</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>B. cereus</italic></td><td style="border:none;" align="left">CCUG7414T</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">16</td><td style="border:none;" align="center">32</td></tr><tr><td style="border:none;" align="left"><italic>A. fumigatus</italic></td><td style="border:none;" align="left">J7</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td></tr><tr><td style="border:none;" align="left"><italic>C. albicans</italic></td><td style="border:none;" align="left">H-29</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td><td style="border:none;" align="center">&#x0003e;32</td></tr><tr><td style="border:none;" align="left"><italic>IC</italic><sub><italic>50</italic></sub><italic>(&#x003bc;M)</italic></td><td style="border:none;" align="left">HepG2</td><td style="border:none;" align="left">liver</td><td style="border:none;" align="center">29</td><td style="border:none;" align="center">50</td><td style="border:none;" align="center">29</td><td style="border:none;" align="center">9</td><td style="border:none;" align="center">13</td><td style="border:none;" align="center">9</td><td style="border:none;" align="center">11</td><td style="border:none;" align="center">14</td></tr><tr><td style="border:none;" align="left"><italic>IC</italic><sub><italic>50</italic></sub><italic>(&#x003bc;g/mL)</italic></td><td style="border:none;" align="left">HepG2</td><td style="border:none;" align="left">liver</td><td style="border:none;" align="center">33</td><td style="border:none;" align="center">56</td><td style="border:none;" align="center">33</td><td style="border:none;" align="center">10</td><td style="border:none;" align="center">14</td><td style="border:none;" align="center">10</td><td style="border:none;" align="center">13</td><td style="border:none;" align="center">16</td></tr><tr><td style="border:none;" align="left"><italic>Hemolysis (%)</italic></td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="center">4.2</td><td style="border:none;" align="center">0.8</td><td style="border:none;" align="center">3.0</td><td style="border:none;" align="center">9.1</td><td style="border:none;" align="center">5.2</td><td style="border:none;" align="center">27.5</td><td style="border:none;" align="center">14.1</td><td style="border:none;" align="center">52.3</td></tr></tbody></table></table-wrap><p>Given the interesting pattern of antibacterial activities
of <bold>2</bold>, along with the favorable IC<sub>50</sub> value
and hemolysis
rate, compound <bold>2</bold> was selected for further studies of
biological properties, and the compound was thus tested against a
wide range of clinically relevant bacterial isolates (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). The compound had good activity
against the WHO top-priority pathogens carbapenem-resistant <italic>A. baumannii</italic>, <italic>E. coli</italic>, and <italic>P. aeruginosa</italic>, with MICs ranging from 1 to 4 &#x003bc;g/mL. Compound <bold>2</bold> was also active against colistin-resistant strains of <italic>A.
baumannii</italic>, <italic>E. coli</italic>, and <italic>K. pneumoniae</italic>, with MICs of 8 &#x003bc;g/mL, 2 &#x003bc;g/mL, and 4 &#x003bc;g/mL, respectively,
as well as against the clinical multidrug-resistant <italic>K. pneumoniae</italic> CH3498, MIC 8 &#x003bc;g/mL (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). The activity of <bold>2</bold> against these important
pathogens makes this compound very interesting for further studies,
with the ultimate aim to develop a new antibiotic drug.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Selected MIC Values (&#x003bc;g/mL)
for Compound <bold>2</bold> after Testing against an Extended Panel
Bacterial Isolates (WT, wild type; MDR, multidrug-resistant; Col,
Colistin; CARBA, Carbapenem; ESC, Extended-spectrum cephalosporin;
CIP, Ciprofloxacin; GEN, Gentamicin; SXT, Trimethoprim-sulfamethoxazole;
mcr-1, Mobilized colistin resistance gene; AMK, Amikacin; TET, Tetracycline)</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="center"/></colgroup><thead><tr><th style="border:none;" align="center">pathogen</th><th style="border:none;" align="center">strain
ID</th><th style="border:none;" align="center">type/resistance pattern</th><th style="border:none;" align="center">MIC</th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">ATCC19606</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">BM4454</td><td style="border:none;" align="left">MDR clinical</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">BM4652</td><td style="border:none;" align="left">efflux-defective derivative of BM4454</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">EN0287</td><td style="border:none;" align="left">Col</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">A219</td><td style="border:none;" align="left">CARBA</td><td style="border:none;" align="center">2<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>A. baumannii</italic></td><td style="border:none;" align="left">A250</td><td style="border:none;" align="left">CARBA</td><td style="border:none;" align="center">2<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">ATCC25922</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">CH3130</td><td style="border:none;" align="left">&#x00394;tolC mutant isogenic to ATCC25922</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">D22</td><td style="border:none;" align="left">lpxC mutant, hypersensitive</td><td style="border:none;" align="center">4</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">CH3491</td><td style="border:none;" align="left">ESC,
CIP, GEN, SXT</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>E.
coli</italic></td><td style="border:none;" align="left">CH9623</td><td style="border:none;" align="left">mcr-1</td><td style="border:none;" align="center">2</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">CH9624</td><td style="border:none;" align="left">mcr-1</td><td style="border:none;" align="center">2</td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">ATCC25922</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">1<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">EC4129</td><td style="border:none;" align="left">CARBA</td><td style="border:none;" align="center">2<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>E. coli</italic></td><td style="border:none;" align="left">EC4163</td><td style="border:none;" align="left">CARBA</td><td style="border:none;" align="center">1<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>K.&#x000a0;pneumoniae</italic></td><td style="border:none;" align="left">ATCC13833</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">4</td></tr><tr><td style="border:none;" align="left"><italic>K.&#x000a0;pneumoniae</italic></td><td style="border:none;" align="left">1161486</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>K.&#x000a0;pneumoniae</italic></td><td style="border:none;" align="left">1161486a</td><td style="border:none;" align="left">&#x00394;tolC mutant isogenic to 1161486</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>K.&#x000a0;pneumoniae</italic></td><td style="border:none;" align="left">CH3498</td><td style="border:none;" align="left">ESC, CARBA, CIP, GEN, AMK, SXT,
TET SXT, TET</td><td style="border:none;" align="center">8</td></tr><tr><td style="border:none;" align="left"><italic>K.&#x000a0;pneumoniae</italic></td><td style="border:none;" align="left">CH9625</td><td style="border:none;" align="left">Col</td><td style="border:none;" align="center">4</td></tr><tr><td style="border:none;" align="left"><italic>K.&#x000a0;pneumoniae</italic></td><td style="border:none;" align="left">CH9626</td><td style="border:none;" align="left">Col</td><td style="border:none;" align="center">4</td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic></td><td style="border:none;" align="left">PAO1</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">32</td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic></td><td style="border:none;" align="left">PAO750</td><td style="border:none;" align="left">efflux-defective isogenic to PAO1</td><td style="border:none;" align="center">32</td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic></td><td style="border:none;" align="left">ATCC27853</td><td style="border:none;" align="left">WT</td><td style="border:none;" align="center">4<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic></td><td style="border:none;" align="left">PS826</td><td style="border:none;" align="left">CARBA</td><td style="border:none;" align="center">4<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr><tr><td style="border:none;" align="left"><italic>P. aeruginosa</italic></td><td style="border:none;" align="left">PS992</td><td style="border:none;" align="left">CARBA</td><td style="border:none;" align="center">4<xref rid="t3fn1" ref-type="table-fn">a</xref></td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Determined at the Public Health
Agency of Sweden.</p></fn></table-wrap-foot></table-wrap><p>The previously
described pedopeptins<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> were shown to have
antibacterial activity against <italic>E. coli</italic>, <italic>S.
aureus</italic>, and <italic>S. epidermis</italic>,
with MICs down to 2 &#x003bc;g/mL against the two tested <italic>E.
coli</italic> strains and down to 4 &#x003bc;g/mL against the two tested
Staphylococcii.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> The MICs for pedopeptins
against two different <italic>E. coli</italic> strains are similar
to MICs determined for compound <bold>2</bold> against several <italic>E. coli</italic> strains, but the activity against <italic>S. aureus</italic> is strikingly different for <bold>2</bold> compared to the pedopeptins.
Possibly, this may be due to differences between the bacterial strains
used in the two studies, but it may also depend on the structural
differences between <bold>2</bold> and the pedopeptins.</p><p>To investigate
the mechanism of action of <bold>2</bold> and to
measure the frequency of resistance (FoR), two <italic>E. coli</italic> strains were incubated with compound <bold>2</bold> at 4 &#x000d7;
MIC and 8 &#x000d7; MIC. In these experiments, however, no resistant
mutants were observed (FoR &#x0003c; 2 &#x000d7; 10<sup>&#x02013;9</sup> and
&#x0003c;3 &#x000d7; 10<sup>&#x02013;9</sup>, respectively), and thus, no information
on the mechanism of action could be obtained by sequencing of resistant
mutants. The pedopeptins, similar peptides from <italic>Pedobacter</italic> sp. SANK 72003,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> have been shown to
inhibit the binding of bacterial LPS to cellular receptors at very
low concentrations (IC<sub>50</sub> 11&#x02013;47 nM).<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Given the similarities between the pedopeptins and the
isopedopeptins (<bold>1</bold>&#x02013;<bold>8</bold>), it is possible
that also <bold>1</bold>&#x02013;<bold>8</bold> may interact with cellular
LPS receptors. In the same study, Kozuma et al. found that also polymyxin
B inhibits the binding of LPS to cellular receptors at even lower
concentrations (3.6 nM) than the pedopeptins.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> The antibiotic compound colistin, which is a polymyxin B analogue,
has been described to have specific interactions with bacterial LPS
but also general detergent type membrane effects.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> Colistin and polymyxin B are both polycationic due to the
presence of the amino functions of the five DABA side-chains in their
structures. Compounds <bold>1</bold>&#x02013;<bold>8</bold> and the
pedopeptins, with one DABA and two DAPA residues, are also cationic
at physiological pH. Cationic peptides are well-documented to interact
with negative structure elements of membrane components,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> and likely, <bold>1</bold>&#x02013;<bold>8</bold> exert their activity by interaction with bacterial membranes. Potentially, <bold>1</bold>&#x02013;<bold>8</bold> and the pedopeptins have a similar
mechanism of action to that of colistin, i.e., binding to LPS and
a general detergent effect on bacterial cytoplasmic membranes. However,
in the present study, compound <bold>2</bold> was found to have potent
activity also against colistin-resistant strains of <italic>A. baumannii</italic>, <italic>E. coli</italic>, and <italic>K. pneumoniae</italic> (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). The <italic>E.
coli</italic> strains carrying the mobilized colistin resistance gene
(<italic>mcr-1</italic>, <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>) have an LPS with phosphoetanolamine residues bound to the
lipid A part, which decreases the affinity for colistin.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> Thus, if there is an interaction of <bold>2</bold> with LPS, this must be different compared to the interaction of
colistin and polymyxin B with LPS.</p><p>In addition to colistin type
peptides, also other antibacterial
lipopeptides have been reported to interact with bacterial membranes,
e.g., the antibiotic drug daptomycin, which has been shown to have
a calcium-dependent aggregation in bacterial cell membranes, which
creates leakage.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> To investigate if permeabilization
of bacterial membranes could be responsible for the activity of the
cationic cyclic isopedopeptins, compound <bold>6</bold> was tested
in an <italic>in vitro</italic> bacterial membrane system using large
unilamellar liposomes made from an <italic>E. coli</italic> phospholipid
extract. Indeed, compound <bold>6</bold> was found to cause membrane
leakage, and the half maximal effective concentration (EC<sub>50</sub>) was 2.0 &#x003bc;M (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). In comparison, the cyclic lipopeptide polymyxin B and the
human antimicrobial peptide LL-37, two highly potent membrane disrupting
antibacterial agents, gave EC<sub>50</sub>&#x02019;s of 1 &#x003bc;M
and 0.6 &#x003bc;M, respectively (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). Bacterial liposome permeabilization has a strong
correlation with antibacterial activity and indicates that compound <bold>6</bold> exerts antibacterial activity by membrane disruption. Due
to the structural similarities between all the isopedopeptins (<bold>1</bold>&#x02013;<bold>8</bold>), it is reasonable to suggest that
this could be a shared mechanism of action that at least in part explains
their antibacterial activity.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Compound <bold>6</bold> tested for leakage generation
on <italic>E. coli</italic> liposomes, along with the known membrane
disrupting
lipopeptide polymyxin B and the human antimicrobial peptide LL-37.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb0c00568_0004" id="gr4" position="float"/></fig></sec></sec><sec id="sec3"><title>Conclusions</title><p>The cyclic lipodepsipeptides
isopedopeptin A&#x02013;H (<bold>1</bold>&#x02013;<bold>8</bold>) described
in the present paper have interesting
activity against WHO top-prioritized Gram-negative bacteria. In particular,
isopedopeptin B (<bold>2</bold>), with potent antibacterial activity
combined with acceptable cytotoxicity and hemolysis rates, along with
a low FoR, is a promising candidate for further studies and optimization
with the goal to develop a new antibiotic drug. The isopedopeptins
form the basis of a recently published Patent Cooperation Treaty (PCT)
application.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup></p></sec></body><back><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information
is available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acschembio.0c00568?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acschembio.0c00568</ext-link>.<list id="silist" list-type="simple"><list-item><p>Methods, tabulated NMR
data for compounds <bold>1</bold>&#x02013;<bold>8</bold>, one-dimensional <sup>1</sup>H NMR spectra
for <bold>1</bold>&#x02013;<bold>8</bold>, one-dimensional <sup>13</sup>C NMR spectra for <bold>1</bold> and <bold>2</bold>, <sup>1</sup>H&#x02013;<sup>1</sup>H COSY spectra for <bold>1</bold>&#x02013;<bold>8</bold>, <sup>1</sup>H&#x02013;<sup>13</sup>C HSQC spectra for <bold>1</bold>&#x02013;<bold>8</bold>, <sup>1</sup>H&#x02013;<sup>13</sup>C HMBC spectra for <bold>1</bold>&#x02013;<bold>8</bold>, ROESY spectra
for <bold>1</bold>&#x02013;<bold>8</bold>, <sup>1</sup>H&#x02013;<sup>1</sup>H TOCSY spectra for <bold>1</bold>&#x02013;<bold>2</bold>,
HR-MS spectra for <bold>1</bold>&#x02013;<bold>8</bold>, MSMS spectra
for <bold>1</bold>&#x02013;<bold>8</bold>, and retention times for <bold>1</bold>&#x02013;<bold>8</bold> from advanced Marfey&#x02019;s analysis
(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acschembio.0c00568/suppl_file/cb0c00568_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cb0c00568_si_001.pdf"><caption><p>cb0c00568_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes-2"><title>Author Contributions</title><p>C.N., J.B.,
J.J.L., B.G., B.&#x000d6;., and A.B. designed the study. C.N., J.B.,
J.J.L., and A.B. did the laboratory work, except for the membrane
permeabilization assay (A.A.S.), the cytotoxicity assays (R.L.), the
extended MIC determination (D.H and S.C.), the FoR determination (D.H
and S.C.), and hemolysis assay (D.H. and S.C.). A.B. wrote the first
manuscript draft, supported by all authors, and all authors contributed
to the subsequent editing of the manuscript. All authors have given
approval to the final version of the manuscript.</p></notes><notes notes-type="COI-statement" id="notes-3"><p>The authors
declare the following competing financial interest(s): C.N., J.B.,
J.J.L., B.G., B.O., and A.B. are shareholders of Ultupharma AB, which
owns the IP rights to the published findings.</p></notes><ack><title>Acknowledgments</title><p>Funding
from Ultupharma AB to C.N., J.B., J.J.L., B.G., and
A.B. is gratefully acknowledged.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Cassini</surname><given-names>A.</given-names></name>; <name><surname>Hogberg</surname><given-names>L. D.</given-names></name>; <name><surname>Plachouras</surname><given-names>D.</given-names></name>; <name><surname>Quattrocchi</surname><given-names>A.</given-names></name>; <name><surname>Hoxha</surname><given-names>A.</given-names></name>; <name><surname>Simonsen</surname><given-names>G. S.</given-names></name>; <name><surname>Colomb-Cotinat</surname><given-names>M.</given-names></name>; <name><surname>Kretzschmar</surname><given-names>M. E</given-names></name>; <name><surname>Devleesschauwer</surname><given-names>B.</given-names></name>; <name><surname>Cecchini</surname><given-names>M.</given-names></name>; <name><surname>Ouakrim</surname><given-names>D. A.</given-names></name>; <name><surname>Oliveira</surname><given-names>T. C.</given-names></name>; <name><surname>Struelens</surname><given-names>M. J</given-names></name>; <name><surname>Suetens</surname><given-names>C.</given-names></name>; <name><surname>Monnet</surname><given-names>D. L</given-names></name>; <name><surname>Strauss</surname><given-names>R.</given-names></name>; <name><surname>Mertens</surname><given-names>K.</given-names></name>; <name><surname>Struyf</surname><given-names>T.</given-names></name>; <name><surname>Catry</surname><given-names>B.</given-names></name>; <name><surname>Latour</surname><given-names>K.</given-names></name>; <name><surname>Ivanov</surname><given-names>I. N</given-names></name>; <name><surname>Dobreva</surname><given-names>E. G</given-names></name>; <name><surname>Tambic
Andrasevic</surname><given-names>A.</given-names></name>; <name><surname>Soprek</surname><given-names>S.</given-names></name>; <name><surname>Budimir</surname><given-names>A.</given-names></name>; <name><surname>Paphitou</surname><given-names>N.</given-names></name>; <name><surname>Zemlickova</surname><given-names>H.</given-names></name>; <name><surname>Schytte Olsen</surname><given-names>S.</given-names></name>; <name><surname>Wolff Sonksen</surname><given-names>U.</given-names></name>; <name><surname>Martin</surname><given-names>P.</given-names></name>; <name><surname>Ivanova</surname><given-names>M.</given-names></name>; <name><surname>Lyytikainen</surname><given-names>O.</given-names></name>; <name><surname>Jalava</surname><given-names>J.</given-names></name>; <name><surname>Coignard</surname><given-names>B.</given-names></name>; <name><surname>Eckmanns</surname><given-names>T.</given-names></name>; <name><surname>Abu Sin</surname><given-names>M.</given-names></name>; <name><surname>Haller</surname><given-names>S.</given-names></name>; <name><surname>Daikos</surname><given-names>G. L</given-names></name>; <name><surname>Gikas</surname><given-names>A.</given-names></name>; <name><surname>Tsiodras</surname><given-names>S.</given-names></name>; <name><surname>Kontopidou</surname><given-names>F.</given-names></name>; <name><surname>Toth</surname><given-names>A.</given-names></name>; <name><surname>Hajdu</surname><given-names>A.</given-names></name>; <name><surname>Guolaugsson</surname><given-names>O.</given-names></name>; <name><surname>Kristinsson</surname><given-names>K. G</given-names></name>; <name><surname>Murchan</surname><given-names>S.</given-names></name>; <name><surname>Burns</surname><given-names>K.</given-names></name>; <name><surname>Pezzotti</surname><given-names>P.</given-names></name>; <name><surname>Gagliotti</surname><given-names>C.</given-names></name>; <name><surname>Dumpis</surname><given-names>U.</given-names></name>; <name><surname>Liuimiene</surname><given-names>A.</given-names></name>; <name><surname>Perrin</surname><given-names>M.</given-names></name>; <name><surname>Borg</surname><given-names>M. A</given-names></name>; <name><surname>de Greeff</surname><given-names>S. C</given-names></name>; <name><surname>Monen</surname><given-names>J. C.</given-names></name>; <name><surname>Koek</surname><given-names>M. B.</given-names></name>; <name><surname>Elstr&#x000f8;m</surname><given-names>P.</given-names></name>; <name><surname>Zabicka</surname><given-names>D.</given-names></name>; <name><surname>Deptula</surname><given-names>A.</given-names></name>; <name><surname>Hryniewicz</surname><given-names>W.</given-names></name>; <name><surname>Canica</surname><given-names>M.</given-names></name>; <name><surname>Nogueira</surname><given-names>P. J.</given-names></name>; <name><surname>Fernandes</surname><given-names>P. A.</given-names></name>; <name><surname>Manageiro</surname><given-names>V.</given-names></name>; <name><surname>Popescu</surname><given-names>G. A</given-names></name>; <name><surname>Serban</surname><given-names>R. I</given-names></name>; <name><surname>Schreterova</surname><given-names>E.</given-names></name>; <name><surname>Litvova</surname><given-names>S.</given-names></name>; <name><surname>Stefkovicova</surname><given-names>M.</given-names></name>; <name><surname>Kolman</surname><given-names>J.</given-names></name>; <name><surname>Klavs</surname><given-names>I.</given-names></name>; <name><surname>Korosec</surname><given-names>A.</given-names></name>; <name><surname>Aracil</surname><given-names>B.</given-names></name>; <name><surname>Asensio</surname><given-names>A.</given-names></name>; <name><surname>Perez-Vazquez</surname><given-names>M.</given-names></name>; <name><surname>Billstrom</surname><given-names>H.</given-names></name>; <name><surname>Larsson</surname><given-names>S.</given-names></name>; <name><surname>Reilly</surname><given-names>J. S</given-names></name>; <name><surname>Johnson</surname><given-names>A.</given-names></name>; <name><surname>Hopkins</surname><given-names>S.</given-names></name> (<year>2019</year>) <article-title>Attributable deaths and disability-adjusted life-years
caused by infections with antibiotic-resistant bacteria in the EU
and the European Economic Area in 2015: a population-level modelling
analysis</article-title>. <source>Lancet Infect. Dis.</source>
<volume>19</volume>, <fpage>56</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30605-4</pub-id>.<pub-id pub-id-type="pmid">30409683</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="book" id="cit2"><person-group><collab>CDC</collab></person-group>. Antibiotic
Resistance Threats
in the United States, 2019. <publisher-name>U.S. Department of Health
and Human Services, CDC</publisher-name>: <publisher-loc>Atlanta,
GA</publisher-loc>, <year>2019</year>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Trimble</surname><given-names>M. J.</given-names></name>; <name><surname>Mlyn&#x000e1;r&#x0010d;ik</surname><given-names>P.</given-names></name>; <name><surname>Kol&#x000e1;&#x00159;</surname><given-names>M.</given-names></name>; <name><surname>Hancock</surname><given-names>R. E. W.</given-names></name> (<year>2016</year>) <article-title>Polymyxin: Alternative Mechanisms of Action and Resistance</article-title>. <source>Cold Spring Harbor Perspect. Med.</source>
<volume>6</volume>, <fpage>a025288</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a025288</pub-id>.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Qin</surname><given-names>W.</given-names></name>; <name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Fang</surname><given-names>S.</given-names></name>; <name><surname>Qiu</surname><given-names>J.</given-names></name> (<year>2015</year>) <article-title>Antibacterial
Mechanisms
of Polymyxin and Bacterial Resistance</article-title>. <source>BioMed
Res. Int.</source>
<volume>2015</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2015/679109</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Straus</surname><given-names>K. S.</given-names></name>; <name><surname>Hancock</surname><given-names>R. E. W.</given-names></name> (<year>2006</year>) <article-title>Mode of action
of the new antibiotic for Gram-positive
pathogens daptomycin: Comparison with cationic antimicrobial peptides
and lipopeptides</article-title>. <source>Biochim. Biophys. Acta, Biomembr.</source>
<volume>1758</volume>, <fpage>1215</fpage>&#x02013;<lpage>1223</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2006.02.009</pub-id>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Harvey</surname><given-names>A. L.</given-names></name>; <name><surname>Edrada-Ebel</surname><given-names>R.</given-names></name>; <name><surname>Quinn</surname><given-names>R. J.</given-names></name> (<year>2015</year>) <article-title>The re-emergence of natural products
for drug discovery in the genomics era</article-title>. <source>Nat.
Rev. Drug Discovery</source>
<volume>14</volume>, <fpage>111</fpage>&#x02013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4510</pub-id>.<pub-id pub-id-type="pmid">25614221</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Genilloud</surname><given-names>O.</given-names></name> (<year>2014</year>) <article-title>The re-emerging
role of microbial natural products in antibiotic discovery</article-title>. <source>Antonie van Leeuwenhoek</source>
<volume>106</volume>, <fpage>173</fpage>&#x02013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1007/s10482-014-0204-6</pub-id>.<pub-id pub-id-type="pmid">24923558</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Ling</surname><given-names>L. L.</given-names></name>; <name><surname>Schneider</surname><given-names>T.</given-names></name>; <name><surname>Peoples</surname><given-names>A. J.</given-names></name>; <name><surname>Spoering</surname><given-names>A. L.</given-names></name>; <name><surname>Engels</surname><given-names>I.</given-names></name>; <name><surname>Conlon</surname><given-names>B. P.</given-names></name>; <name><surname>Mueller</surname><given-names>A.</given-names></name>; <name><surname>Sch&#x000e4;berle</surname><given-names>T. F.</given-names></name>; <name><surname>Hughes</surname><given-names>D. E.</given-names></name>; <name><surname>Epstein</surname><given-names>S.</given-names></name>; <name><surname>Jones</surname><given-names>M.</given-names></name>; <name><surname>Lazarides</surname><given-names>L.</given-names></name>; <name><surname>Steadman</surname><given-names>V. A.</given-names></name>; <name><surname>Cohen</surname><given-names>D. R.</given-names></name>; <name><surname>Felix</surname><given-names>C. R.</given-names></name>; <name><surname>Fetterman</surname><given-names>K. A.</given-names></name>; <name><surname>Millett</surname><given-names>W. P.</given-names></name>; <name><surname>Nitti</surname><given-names>A. G.</given-names></name>; <name><surname>Zullo</surname><given-names>A. M.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Lewis</surname><given-names>K.</given-names></name> (<year>2015</year>) <article-title>A new antibiotic kills pathogens without detectable resistance</article-title>. <source>Nature</source>
<volume>517</volume>, <fpage>455</fpage>&#x02013;<lpage>459</lpage>. <pub-id pub-id-type="doi">10.1038/nature14098</pub-id>.<pub-id pub-id-type="pmid">25561178</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Nichols</surname><given-names>D.</given-names></name>; <name><surname>Cahoon</surname><given-names>N.</given-names></name>; <name><surname>Trakhtenberg</surname><given-names>E. M.</given-names></name>; <name><surname>Pham</surname><given-names>L.</given-names></name>; <name><surname>Mehta</surname><given-names>A.</given-names></name>; <name><surname>Belanger</surname><given-names>A.</given-names></name>; <name><surname>Kanigan</surname><given-names>T.</given-names></name>; <name><surname>Lewis</surname><given-names>K.</given-names></name>; <name><surname>Epstein</surname><given-names>S. S.</given-names></name> (<year>2010</year>) <article-title>Use of
Ichip for High-Throughput <italic>In Situ</italic> Cultivation of
&#x0201c;Uncultivable&#x0201d; Microbial Species</article-title>. <source>Appl. Environ. Microbiol.</source>
<volume>76</volume>, <fpage>2445</fpage>&#x02013;<lpage>2450</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.01754-09</pub-id>.<pub-id pub-id-type="pmid">20173072</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Thaker</surname><given-names>M. N.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Spanogiannopoulos</surname><given-names>P.</given-names></name>; <name><surname>Waglechner</surname><given-names>N.</given-names></name>; <name><surname>King</surname><given-names>A. M.</given-names></name>; <name><surname>Medina</surname><given-names>R.</given-names></name>; <name><surname>Wright</surname><given-names>G. D.</given-names></name> (<year>2013</year>) <article-title>Identifying producers
of antibacterial compounds by screening for antibiotic resistance</article-title>. <source>Nat. Biotechnol.</source>
<volume>31</volume>, <fpage>922</fpage>&#x02013;<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2685</pub-id>.<pub-id pub-id-type="pmid">24056948</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Namikoshi</surname><given-names>M.</given-names></name>; <name><surname>Choi</surname><given-names>B. W.</given-names></name>; <name><surname>Sakai</surname><given-names>R.</given-names></name>; <name><surname>Sun</surname><given-names>F.</given-names></name>; <name><surname>Rinehart</surname><given-names>K. L.</given-names></name>; <name><surname>Carmichael</surname><given-names>W. W.</given-names></name>; <name><surname>Evans</surname><given-names>W. R.</given-names></name>; <name><surname>Cruz</surname><given-names>P.</given-names></name>; <name><surname>Munro</surname><given-names>M. H. G.</given-names></name>; <name><surname>Blunt</surname><given-names>J. W.</given-names></name> (<year>1994</year>) <article-title>New Nodularins: A General Method for Structure Assignment</article-title>. <source>J. Org. Chem.</source>
<volume>59</volume>, <fpage>2349</fpage>&#x02013;<lpage>2357</lpage>. <pub-id pub-id-type="doi">10.1021/jo00088a014</pub-id>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Sano</surname><given-names>T.</given-names></name>; <name><surname>Kaya</surname><given-names>K.</given-names></name> (<year>1998</year>) <article-title>Two New (<italic>E</italic>)-2-Amino-2-Butenoic Acid (Dhb)-Containing
Microcystins Isolated from <italic>Oscillatoria agardhii</italic></article-title>. <source>Tetrahedron</source>
<volume>54</volume>, <fpage>463</fpage>&#x02013;<lpage>470</lpage>. <pub-id pub-id-type="doi">10.1016/S0040-4020(97)10291-5</pub-id>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Dale</surname><given-names>J. A.</given-names></name>; <name><surname>Mosher</surname><given-names>H. S.</given-names></name> (<year>1973</year>) <article-title>Nuclear magnetic resonance enantiomer
reagents. Configurational
correlation via nuclear magnetic resonance chemical shifts of diastereomericmandelate,
O-methylmandelate, and &#x003b1;-methoxy-&#x003b1;-trifluorophenylacetate
(MTPA) esters</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>95</volume>, <fpage>512</fpage>&#x02013;<lpage>519</lpage>. <pub-id pub-id-type="doi">10.1021/ja00783a034</pub-id>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Harada</surname><given-names>K.</given-names></name>; <name><surname>Fujii</surname><given-names>K.</given-names></name>; <name><surname>Mayumi</surname><given-names>T.</given-names></name>; <name><surname>Hibino</surname><given-names>Y.</given-names></name>; <name><surname>Suzuki</surname><given-names>M.</given-names></name>; <name><surname>Ikai</surname><given-names>Y.</given-names></name>; <name><surname>Oka</surname><given-names>H.</given-names></name> (<year>1995</year>) <article-title>Constituent
Amino Acids in Peptide
--- Advanced Marfey&#x02019;s Method</article-title>. <source>Tetrahedron
Lett.</source>
<volume>36</volume>, <fpage>1515</fpage>&#x02013;<lpage>1518</lpage>. <pub-id pub-id-type="doi">10.1016/0040-4039(95)00078-Q</pub-id>.</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Fujii</surname><given-names>K.</given-names></name>; <name><surname>Ikai</surname><given-names>Y.</given-names></name>; <name><surname>Mayumi</surname><given-names>T.</given-names></name>; <name><surname>Oka</surname><given-names>H.</given-names></name>; <name><surname>Suzuki</surname><given-names>M.</given-names></name>; <name><surname>Harada</surname><given-names>K.</given-names></name> (<year>1997</year>) <article-title>A Nonempirical Method Using LC/MS for Determination
of the Absolute Configuration of Constituent Amino Acids in a Peptide:
Elucidation of Limitations of Marfey&#x02019;s Method and of Its Separation
Mechanism</article-title>. <source>Anal. Chem.</source>
<volume>69</volume>, <fpage>3346</fpage>&#x02013;<lpage>3352</lpage>. <pub-id pub-id-type="doi">10.1021/ac9701795</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Kj&#x000e6;r</surname><given-names>A.</given-names></name>; <name><surname>Larsen</surname><given-names>P. O.</given-names></name>; <name><surname>Sillen</surname><given-names>L. G.</given-names></name>; <name><surname>Andersson</surname><given-names>G.</given-names></name>; <name><surname>Stenhagen</surname><given-names>E.</given-names></name>; <name><surname>Palmstierna</surname><given-names>H.</given-names></name> (<year>1959</year>) <article-title>Amino Acid
Studies. Part II. Structure
and Synthesis of Albizziine (L-2-Amino-3-ureidopropionic Acid), and
Amino Acid from Higher Plants</article-title>. <source>Acta Chem. Scand.</source>
<volume>13</volume>, <fpage>1565</fpage>&#x02013;<lpage>1574</lpage>. <pub-id pub-id-type="doi">10.3891/acta.chem.scand.13-1565</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Hirota-Takahata</surname><given-names>Y.</given-names></name>; <name><surname>Kozuma</surname><given-names>S.</given-names></name>; <name><surname>Kuraya</surname><given-names>N.</given-names></name>; <name><surname>Fukuda</surname><given-names>D.</given-names></name>; <name><surname>Nakajima</surname><given-names>M.</given-names></name>; <name><surname>Ando</surname><given-names>O.</given-names></name> (<year>2014</year>) <article-title>Pedopeptins, novel
inhibitors of LPS: Taxonomy of producing organism,
fermentation, isolation, physicochemical properties and structural
elucidation</article-title>. <source>J. Antibiot.</source>
<volume>67</volume>, <fpage>243</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1038/ja.2013.122</pub-id>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="patent" id="cit18"><person-group person-group-type="allauthors"><name><surname>Mutsuo</surname><given-names>N.</given-names></name>, <name><surname>Yuki</surname><given-names>H.</given-names></name>, <name><surname>Osamu</surname><given-names>A.</given-names></name>, <name><surname>Nahojiyu</surname><given-names>K.</given-names></name>, <name><surname>Shiho</surname><given-names>K.</given-names></name>,
and <name><surname>Daisuke</surname><given-names>F.</given-names></name></person-group><article-title>B-12489 Substance and Method for Producing
the Same</article-title>. <patent>JP2005200324(A)</patent>, July 28th, 2005.</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Kozuma</surname><given-names>S.</given-names></name>; <name><surname>Hirota-Takahata</surname><given-names>Y.</given-names></name>; <name><surname>Fukuda</surname><given-names>D.</given-names></name>; <name><surname>Kuraya</surname><given-names>N.</given-names></name>; <name><surname>Nakajima</surname><given-names>M.</given-names></name>; <name><surname>Ando</surname><given-names>O.</given-names></name> (<year>2014</year>) <article-title>Screening and biological activities
of pedopeptins, novel inhibitors
of LPS produced by soil bacteria</article-title>. <source>J. Antibiot.</source>
<volume>67</volume>, <fpage>237</fpage>&#x02013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1038/ja.2013.121</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Liu</surname><given-names>Y.-Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Walsh</surname><given-names>T. R.</given-names></name>; <name><surname>Yi</surname><given-names>L.-X.</given-names></name>; <name><surname>Zhang</surname><given-names>R.</given-names></name>; <name><surname>Spencer</surname><given-names>J.</given-names></name>; <name><surname>Doi</surname><given-names>Y.</given-names></name>; <name><surname>Tian</surname><given-names>G.</given-names></name>; <name><surname>Dong</surname><given-names>B.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Yu</surname><given-names>L.-F.</given-names></name>; <name><surname>Gu</surname><given-names>D.</given-names></name>; <name><surname>Ren</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Lv</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>D.</given-names></name>; <name><surname>Zhou</surname><given-names>H.</given-names></name>; <name><surname>Liang</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>J.-H.</given-names></name>; <name><surname>Shen</surname><given-names>J.</given-names></name> (<year>2016</year>) <article-title>Emergence
of plasmid-mediated
colistin resistance mechanism MCR-1 in animals and human beings in
China: a microbiological and molecular biological study</article-title>. <source>Lancet Infect. Dis.</source>
<volume>16</volume>, <fpage>161</fpage>&#x02013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(15)00424-7</pub-id>.<pub-id pub-id-type="pmid">26603172</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="patent" id="cit21"><person-group person-group-type="allauthors"><name><surname>&#x000d6;berg</surname><given-names>B.</given-names></name>, <name><surname>Broberg</surname><given-names>A.</given-names></name>, <name><surname>Guss</surname><given-names>B.</given-names></name>, <name><surname>Levenfors</surname><given-names>J.</given-names></name>, <name><surname>Bjerketorp</surname><given-names>J.</given-names></name>, and <name><surname>Nord</surname><given-names>C.</given-names></name></person-group><article-title>Peptide compounds</article-title>. <patent>WO
2020/046190A1</patent>, March 5th, 2020.</mixed-citation></ref></ref-list></back></article>